ClinicalTrials.gg
RecruitingNCT07187570RECUR-AFUpdated Sep 23, 2025

RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care

A Phase 3 interventional study of Dapagliflozin 10 mg once daily in Atrial Fibrillation (AF), sponsored by Region Stockholm. Recruiting at 7 sites in Sweden. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Region Stockholm · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,600
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 135 studies in Atrial Fibrillation with a site in Sweden — 24 open to participants now, 36 under way, 5 of them phase 3. Atrial Fibrillation · Sweden.

Planned enrollment
28th of 95
1,600 · median 361
Started
2025
with 6 others
Phase 3
29 of 135
5 open now
Primary completion
2027-12
later than 19 of 35 live
Registered
128th of 135
by date

Among the 135 studies in Atrial Fibrillation with a site in Sweden, this one is the 28th largest by planned enrollment of the 95 interventional ones that give a count, is one of 7 that started in 2025, is one of 29 in phase 3, reaches primary completion later than 19 of the 35 other live ones, and was the 128th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

24 of the 135 studies in Atrial Fibrillation with a site in Sweden are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Atrial Fibrillation with a site in Sweden, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if drug dapagliflozin, a sodium-glucose transport-2 inhibitor, works to treat atrial fibrillation in adults. The main question it aims to answer is:

  • Does the drug dapagliflozin reduce the recurrence rate of atrial fibrillation?

Researchers will compare drug dapagliflozin to standard therapy to see if drug dapagliflozin reduce the recurrence of atrial fibrillation.

Persons with atrial fibrillation who are planned for an electric cardioversion will:

  • Take the drug dapagliflozin, or no drug, once a day for a maximum of 56 days
  • Undergo a planned electric cardioversion of the atrial fibrillation
  • Record the rhythm with a hand-held device that transmits the signal to researchers during the study period, but no longer than for 56 days
03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

Keywords

  • dapagliflozin
  • sodium-glucose transport-2 inhibitor
  • electric cardioversion
  • hand-held ECG device
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with AF on who are planned for electrical cardioversion within 7-26 days from inclusion-date.
  • Age ≥ 55 years.
  • Provided written .

Exclusion criteria

Exclusion Criteria:

  • Current treatment with an SGLT2 inhibitor.
  • Prior/current diagnosis of heart failure.
  • Type 1 diabetes mellitus.
  • Estimated (eGFR) \< 25 mL/min/1.73m2.
  • Pulmonary vein isolation within preceding 3 months or planned pulmonary vein isolation during the study period (56 days).
  • to SGLT2 inhibitors.
  • Any condition or circumstance in which the patient should not participate in the study according to the study investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,600 participants (estimated)

Study arms

  • No intervention
    Usual care

    Standard of care

  • Experimental
    Dapagliflozin

    Tablet Dapagliflozin 10 mg once daily

    Drug: Dapagliflozin 10 mg once daily

Interventions

06

What researchers measure

Primary outcomes

  1. Atrial fibrillation recurrence

    Time to first AF recurrence detected with an ECG- monitoring device within 30 days after planned elective electrical cardioversion.

    Time frame: 30 days after elective electrical cardioversion

Secondary outcomes

  1. Proportion of patients in SR at 30 days

    Proportion of patients in SR 30 days after cardioversion.

    Time frame: 30 days after elective electrical cardioversion

  2. Proportion of patients without any atrial fibrillation recurrence at 30 days

    Proportion of patients without any atrial fibrillation recurrence at 30 days

    Time frame: 30 days after elective electrical cardioversion

  3. Time to spontaneous return to sinus rhythm before electrical cardioversion

    Time to spontaneous return to sinus rhythm measured from randomization to electrical cardioversion (max 26 days)

    Time frame: Up to 26 days

  4. Spontaneous return to sinus rhythm before cardioversion.

    Number of patients with return to sinus rhythm at time of electrical cardioversion (maximum 26 days from randomization)

    Time frame: Up to 26 days

  5. Success of cardioversion

    Discharged with sinus rhythm after electric cardioversion

    Time frame: Periprocedural

  6. Total number of days with atrial fibrillation

    Total number of days with AF recordings during the 30 days following cardioversion.

    Time frame: From day of electric cardioversion to 30 days after

  7. Absence of clinical atrial fibrillation recording

    Absence of clinical atrial fibrillation recurrence (12-lead ECG-verified) during follow-up after cardioversion or after spontaneous return to SR (before cardioversion).

    Time frame: From randomization to 30 days after electric cardioversion

07

Study locations

2 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

Of 62 non-industry phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 73. This study's planned 30 months is below that.

Counting every sponsor, half of 83 studies reached it within 42 months; a quarter within 32 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Sep 23, 2025
StartActual
Jun 3, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07187570
Lead sponsor
Region Stockholm
Responsible party
Sponsor
First posted
Sep 23, 2025
Start date
Jun 3, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 23, 2025

Study contacts

Karolina Szummer, MD PhD
Contact
karolina.szummer@regionstockholm.se
+4681238000
Karolina Szummer, MD PhD
principal investigator · Karolinska Institutet
Ziad Hijazi, MD PhD
principal investigator · Dept. of Medical Sciences, Uppsala University, Uppsala, Sweden

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion